s6y AIM ImmunoTech Inc. CORRESP

AIM ImmunoTech Inc. CORRESP, filed Jan 31, 2022: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

 

 

February 1, 2022

 

VIA EDGAR

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

 

  Re: AIM ImmunoTech Inc.
    Registration Statement on Form S-3
    (SEC filing No. 333-262280)
     
    Acceleration Request
    Requested Date: February 4, 2022
    Requested Time: 4:00 P.M. Eastern Time

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), AIM ImmunoTech Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-262280) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the Commission”).

 

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Feiner via email at rfeiner@silverfirm.com.

 

  Very truly yours,
     
  AIM IMMUNOTECH INC.
     
  By: /s/ Ellen Lintal
    Ellen Lintal,
    Chief Financial Officer

 

cc: Richard Feiner, Esq.

 

Corporate Headquarters          
2117 SW Highway 484, Ocala FL 34473       t: 352-448-7797   f: 352-480-46
Finance & Administration            
604 Main Street, Riverton NJ 08077       t: 352-448-7797   f: 352-480-462
Manufacturing            
783 Jersey Ave, New Brunswick, NJ 08901   www.aimimmuno.com   t: 732-249-3250   f: 732-249-6895